What does Cartalax do?

Cartalax is described as AED, a synthetic Ala-Glu-Asp tripeptide from the Khavinson short-peptide bioregulator group. The supplied evidence frames it as a research compound investigated for cartilage and connective-tissue biology, without FDA approval or registered human trials.

How does Cartalax work?

The proposed model is gene-regulatory rather than a conventional receptor-driven mechanism. The source reports that Khavinson-group work links AED with cartilage-cell gene expression, including SOX9, COL2 and ACAN, and also mentions WNT, ERK-p38 and Smad pathway context. This remains mainly cell and animal evidence rather than established clinical consensus.

Is Cartalax FDA approved?

No. The supplied source lists Cartalax as not FDA approved and describes its status as available in Russia.

What side effects are reported for Cartalax?

The source lists generally good tolerability, possible mild injection-site reactions, transient fatigue, rare mild gastrointestinal upset and limited documented adverse-effect data. These are reported observations, not a complete safety profile.

What typical dose is reported for Cartalax?

The source says community dose information is limited. A research-literature row reports oral use at 10-20 mg daily over 10-30 day courses, but this should be treated as research-context information rather than dosing advice.

Bioregulators Preclinical - animal studies only

Cartalax

Also known as: Ala-Glu-Asp, AED Tripeptide

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

AED tripeptide bioregulator studied in preclinical cartilage research.

Status

Preclinical

Evidence level: animal studies

Typical dose

Limited community data available

Oral

Researched for

Joint health, cartilage support, osteoarthritis

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic AED tripeptide associated with the Khavinson short- bioregulator family.
Researched for joint health, cartilage support and osteoarthritis-related contexts.
Evidence described in the source is , including in-vitro and animal work.
Not FDA approved; the source reports availability in Russia.
Human efficacy is not established in the supplied evidence.

How it's thought to work

Cartalax is presented as AED, a short cytogen for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.

What the research shows

Where the research stands

The supplied research summary places Cartalax in a evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Available in Russia; not FDA approved Not FDA approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community reports do not provide a well-defined Cartalax dose and point back to research protocols; this is not medical guidance.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Research Literature - Observed in studies

Animal study doses may not translate directly to humans.

Duration: 10-30 day courses
Administration: Oral

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source does not establish a specific timing advantage; it suggests that regularity is more relevant than choosing a precise time.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well-tolerated
Mild injection site reactions
Transient fatigue
Mild gastrointestinal upset
Limited documented side-effect data

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Ala-Glu-Asp-OH (AED)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Cartalax

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Cartalax

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions